Skip to content

Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial

Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03438227
Acronym
IVIDA
Enrollment
38
Registered
2018-02-19
Start date
2018-04-15
Completion date
2019-12-31
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anemia of Pregnancy, Iron Malabsorption

Keywords

Iron Deficiency Anemia of Pregnancy, oral iron supplementation, parenteral iron supplementation, maternal anemia

Brief summary

Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. While treatment of iron-deficiency anemia with iron supplementation is recommended, treatment strategies remain controversial: the American College of Obstetrics and Gynecology recommends oral iron supplementation with parental iron reserved for the rare patient who cannot tolerate or will not take oral iron, while United Kingdom professional organizations recommend a more liberal use of parenteral iron. The reason for these disparate recommendations is that few high-quality studies comparing oral to parenteral iron have been conducted in developed countries, and the potential impact of parental iron treatment on obstetric and perinatal outcomes remains unclear. We propose the first randomized-controlled trial in the United States describing the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron.

Detailed description

Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. In the United States, anemia affects nearly 20% of pregnancies and the majority is iron-deficiency anemia. Therefore, treatment of iron-deficiency anemia with iron supplementation is recommended.1 However, there is controversy about the treatment strategies. The American College of Obstetrics and Gynecology recommends oral iron supplementation for iron-deficiency anemia in pregnancy, with parental iron reserved only for the rare patient who cannot tolerate or will not take oral iron (1) Conversely, guidelines from the United Kingdom. are more liberal on the use of parental iron for the treatment of iron-deficiency anemia in pregnancy (2). Both treatment guidelines are based on limited data regarding the risks and benefits of parental iron for treatment of iron-deficiency anemia in pregnancy. The majority of randomized trials were conducted in developing country settings. In fact, few high-quality studies have been conducted in developed countries, and none has been conducted in the United States Moreover, there is limited data from prior studies on the impact of parental iron treatment on perinatal outcomes. The most recent Cochrane review including mostly from trials conducted in low-income countries found that, although parenteral iron improved hemoglobin levels and iron stores than the oral route, no clinical outcomes were assessed and there were insufficient data on adverse effects (3). The authors concluded that large, good quality trials, assessing clinical outcomes including adverse effects … are required (3). This randomized controlled trial aims to assess the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron. We hypothesize that treating iron-deficiency anemia with parental iron is associated with improved maternal and neonatal outcomes compared with a protocol based on oral iron. To increase generalizability of the findings, we will use broad inclusion criteria and analyze data using the intention-to-treat principle.

Interventions

Single intravenous infusion of iron dextran 1000mg.

Oral iron supplementation with ferrous sulfate 325mg one to three times daily

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

The research team will be blinded to the patients' treatment arm. A team of resident physicians who are unfamiliar with the study aims will provide standard obstetric care to all participants.

Intervention model description

All participants at less than 28 weeks gestation will have an anemia evaluation and work up per standard prenatal care. Those who meet a clinical diagnosis of iron-deficiency anemia will initiate oral iron and have their Complete Blood Count rechecked between 24 and 28 weeks gestation. If their hemoglobin is less than 10 mg/dL, they will be randomized to either continue their oral iron supplementation or receive a single intravenous dextran iron transfusion. If the patient is enrolled after 28 weeks and receives a diagnosis of iron deficiency anemia, she will be randomized at that time.

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Iron-deficiency anemia (serum ferritin \<30 micrograms, normal hemoglobin electrophoresis, and hemoglobin \<10 mg/dL), planned delivery at Barnes-Jewish Hospital

Exclusion criteria

* Non-iron-deficiency anemia, multiple gestation, prenatally diagnosed major fetal anomalies, known aneuploidy, planned delivery at other hospital, inability to obtain consent

Design outcomes

Primary

MeasureTime frameDescription
Maternal Anemia at DeliveryAt deliveryNumber of participants with maternal hemoglobin \<11g/dl at delivery

Secondary

MeasureTime frameDescription
Maternal Hemoglobin at DeliveryOn admission to inpatient obstetrics unit for deliveryMaternal hemoglobin on admission to inpatient obstetrics unit for delivery
Number of Participants With Medication Adverse Events2 - 3 days after single intravenous iron infusion or initiation of oral ironParticipants reporting symptoms when contacted by via telephone 2 - 3 days after their infusion of intravenous iron or initiation of oral iron
Maternal Hemoglobin Below 10g/dl at DeliveryAt deliveryNumber of participants with hemoglobin below 10g/dl at delivery
Maternal Ferritin at DeliveryAt deliveryMaternal serum ferritin level in μg/L at delivery
Number of Participants Who Received Blood TransfusionDuring inpatient admission for delivery of neonateParticipant receiving transfusion of packed red blood cells during admission for delivery of infant obtained via medical chart review.
Mode of DeliveryOnce, at infant deliveryWhether infant was delivered vaginally or via cesarean section
Birth WeightObtained once, at infant deliveryNeonatal weight at delivery
Umbilical Cord Arterial pHDrawn once from umbilical cord segment at deliveryUmbilical cord arterial pH obtained at delivery
APGAR Scores at 1 Minutes of LifeObtained at 1 minute of lifeThe APGAR score, named after the Virginia Apgar, pediatrician who came up with it, measures the physical condition of a newborn infant on a scale ranging from a minimum of 0 (worsts) to a maximum of 10 (best).
Neonatal HemoglobinDrawn once from umbilical cord segment at birthNeonatal hemoglobin in g/dl at delivery
Composite Neonatal Morbidity (Defined by the Occurrence of One or More of 10 Neonatal Morbidities.At birthNeonatal morbidity composite, defined by the occurrence of one or more of the following neonatal morbidities: neonatal seizures (diagnosed by clinician), intraventricular hemorrhage (diagnosed by clinician on brain MRI or Ultrasound), hypoxic-ischemic encephalopathy (diagnosed by clinician), neonatal hypothermic therapy (brain cooling as documented on inpatient record, sepsis (diagnosed by blood culture), respiratory distress syndrome (diagnosed by clinician), hyperbilirubinemia requiring photo therapy (diagnosed by clinician), birth injury (diagnosed by clinician), or meconium aspiration syndrome (diagnosed by clinician), neonatal intensive care unit admission (documented in the inpatient record).
Neonatal FerritinDrawn once from umbilical cord segment at birthNeonatal ferritin in ug/L at delivery
Gestational Age at DeliveryOnce, at infant deliveryGestational age in weeks at delivery

Countries

United States

Participant flow

Participants by arm

ArmCount
Intravenous Iron Dextran Infusion
Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor & Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion Iron dextran: Single intravenous infusion of iron dextran 1000mg.
10
Oral Ferrous Sulfate Supplementation
Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider. Ferrous sulfate 325mg: Oral iron supplementation with ferrous sulfate 325mg one to three times daily
13
Total23

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject105

Baseline characteristics

CharacteristicTotalIntravenous Iron Dextran InfusionOral Ferrous Sulfate Supplementation
Age, Continuous28 years26 years28 years
Chronic hypertension5 Participants2 Participants3 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants0 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
21 Participants10 Participants11 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Nulliparous4 Participants1 Participants3 Participants
Prepregnancy diabetes2 Participants1 Participants1 Participants
Prior preterm birth (<37 weeks' gestation)5 Participants2 Participants3 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
21 Participants10 Participants11 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
2 Participants0 Participants2 Participants
Region of Enrollment
United States
23 participants10 participants13 participants
Sex: Female, Male
Female
23 Participants10 Participants13 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 13
other
Total, other adverse events
3 / 103 / 13
serious
Total, serious adverse events
0 / 100 / 13

Outcome results

Primary

Maternal Anemia at Delivery

Number of participants with maternal hemoglobin \<11g/dl at delivery

Time frame: At delivery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intravenous Iron Dextran InfusionMaternal Anemia at Delivery4 Participants
Oral Ferrous Sulfate SupplementationMaternal Anemia at Delivery11 Participants
p-value: 0.039Chi-squared
Secondary

APGAR Scores at 1 Minutes of Life

The APGAR score, named after the Virginia Apgar, pediatrician who came up with it, measures the physical condition of a newborn infant on a scale ranging from a minimum of 0 (worsts) to a maximum of 10 (best).

Time frame: Obtained at 1 minute of life

ArmMeasureValue (MEDIAN)
Intravenous Iron Dextran InfusionAPGAR Scores at 1 Minutes of Life8 score on a scale
Oral Ferrous Sulfate SupplementationAPGAR Scores at 1 Minutes of Life8 score on a scale
p-value: 0.049Log Rank
Secondary

Birth Weight

Neonatal weight at delivery

Time frame: Obtained once, at infant delivery

ArmMeasureValue (MEAN)Dispersion
Intravenous Iron Dextran InfusionBirth Weight3174.0 gramsStandard Deviation 657.2
Oral Ferrous Sulfate SupplementationBirth Weight3029.2 gramsStandard Deviation 550.5
p-value: 0.571t-test, 2 sided
Secondary

Composite Neonatal Morbidity (Defined by the Occurrence of One or More of 10 Neonatal Morbidities.

Neonatal morbidity composite, defined by the occurrence of one or more of the following neonatal morbidities: neonatal seizures (diagnosed by clinician), intraventricular hemorrhage (diagnosed by clinician on brain MRI or Ultrasound), hypoxic-ischemic encephalopathy (diagnosed by clinician), neonatal hypothermic therapy (brain cooling as documented on inpatient record, sepsis (diagnosed by blood culture), respiratory distress syndrome (diagnosed by clinician), hyperbilirubinemia requiring photo therapy (diagnosed by clinician), birth injury (diagnosed by clinician), or meconium aspiration syndrome (diagnosed by clinician), neonatal intensive care unit admission (documented in the inpatient record).

Time frame: At birth

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intravenous Iron Dextran InfusionComposite Neonatal Morbidity (Defined by the Occurrence of One or More of 10 Neonatal Morbidities.2 Participants
Oral Ferrous Sulfate SupplementationComposite Neonatal Morbidity (Defined by the Occurrence of One or More of 10 Neonatal Morbidities.4 Participants
p-value: 0.66Fisher Exact
Secondary

Gestational Age at Delivery

Gestational age in weeks at delivery

Time frame: Once, at infant delivery

ArmMeasureValue (MEAN)Dispersion
Intravenous Iron Dextran InfusionGestational Age at Delivery38.1 weeksStandard Deviation 1
Oral Ferrous Sulfate SupplementationGestational Age at Delivery36.9 weeksStandard Deviation 2.3
p-value: 0.15t-test, 2 sided
Secondary

Maternal Ferritin at Delivery

Maternal serum ferritin level in μg/L at delivery

Time frame: At delivery

ArmMeasureValue (MEAN)Dispersion
Intravenous Iron Dextran InfusionMaternal Ferritin at Delivery129.8 μg/LStandard Deviation 117.2
Oral Ferrous Sulfate SupplementationMaternal Ferritin at Delivery26.6 μg/LStandard Deviation 14.6
p-value: 0.19t-test, 2 sided
Secondary

Maternal Hemoglobin at Delivery

Maternal hemoglobin on admission to inpatient obstetrics unit for delivery

Time frame: On admission to inpatient obstetrics unit for delivery

ArmMeasureValue (MEAN)Dispersion
Intravenous Iron Dextran InfusionMaternal Hemoglobin at Delivery11.0 g/dLStandard Deviation 0.7
Oral Ferrous Sulfate SupplementationMaternal Hemoglobin at Delivery9.9 g/dLStandard Deviation 1.1
p-value: 0.019t-test, 2 sided
Secondary

Maternal Hemoglobin Below 10g/dl at Delivery

Number of participants with hemoglobin below 10g/dl at delivery

Time frame: At delivery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intravenous Iron Dextran InfusionMaternal Hemoglobin Below 10g/dl at Delivery1 Participants
Oral Ferrous Sulfate SupplementationMaternal Hemoglobin Below 10g/dl at Delivery7 Participants
p-value: 0.029Fisher Exact
Secondary

Mode of Delivery

Whether infant was delivered vaginally or via cesarean section

Time frame: Once, at infant delivery

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Intravenous Iron Dextran InfusionMode of DeliveryVaginal delivery4 Participants
Intravenous Iron Dextran InfusionMode of DeliveryCesarean delivery6 Participants
Oral Ferrous Sulfate SupplementationMode of DeliveryVaginal delivery8 Participants
Oral Ferrous Sulfate SupplementationMode of DeliveryCesarean delivery5 Participants
p-value: 0.414Chi-squared
Secondary

Neonatal Ferritin

Neonatal ferritin in ug/L at delivery

Time frame: Drawn once from umbilical cord segment at birth

ArmMeasureValue (MEAN)Dispersion
Intravenous Iron Dextran InfusionNeonatal Ferritin169.4 ug/LStandard Deviation 98.2
Oral Ferrous Sulfate SupplementationNeonatal Ferritin147.1 ug/LStandard Deviation 69.2
p-value: 0.633t-test, 2 sided
Secondary

Neonatal Hemoglobin

Neonatal hemoglobin in g/dl at delivery

Time frame: Drawn once from umbilical cord segment at birth

ArmMeasureValue (MEAN)Dispersion
Intravenous Iron Dextran InfusionNeonatal Hemoglobin13.4 g/dLStandard Deviation 3.4
Oral Ferrous Sulfate SupplementationNeonatal Hemoglobin13.5 g/dLStandard Deviation 2.1
p-value: 0.933t-test, 2 sided
Secondary

Number of Participants Who Received Blood Transfusion

Participant receiving transfusion of packed red blood cells during admission for delivery of infant obtained via medical chart review.

Time frame: During inpatient admission for delivery of neonate

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intravenous Iron Dextran InfusionNumber of Participants Who Received Blood Transfusion0 Participants
Oral Ferrous Sulfate SupplementationNumber of Participants Who Received Blood Transfusion2 Participants
p-value: 0.194Fisher Exact
Secondary

Number of Participants With Medication Adverse Events

Participants reporting symptoms when contacted by via telephone 2 - 3 days after their infusion of intravenous iron or initiation of oral iron

Time frame: 2 - 3 days after single intravenous iron infusion or initiation of oral iron

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Intravenous Iron Dextran InfusionNumber of Participants With Medication Adverse EventsSevere0 Participants
Intravenous Iron Dextran InfusionNumber of Participants With Medication Adverse EventsMild/moderate3 Participants
Oral Ferrous Sulfate SupplementationNumber of Participants With Medication Adverse EventsSevere0 Participants
Oral Ferrous Sulfate SupplementationNumber of Participants With Medication Adverse EventsMild/moderate3 Participants
p-value: 0.029Fisher Exact
Secondary

Umbilical Cord Arterial pH

Umbilical cord arterial pH obtained at delivery

Time frame: Drawn once from umbilical cord segment at delivery

ArmMeasureValue (MEAN)Dispersion
Intravenous Iron Dextran InfusionUmbilical Cord Arterial pH7.24 UnitlessStandard Deviation 0.09
Oral Ferrous Sulfate SupplementationUmbilical Cord Arterial pH7.29 UnitlessStandard Deviation 0.05
p-value: 0.12t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026